A Multicentre Study to Evaluate the Safety and Efficacy of AD 923 in Comparison to MSIR for the Treatment of CBP in Subjects

NCT00635063 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
150
Enrollment
INDUSTRY
Sponsor class

Stopped Termination is due to a combination of a device defect potentially impacting the quality of the AD 923 IMP and a major change in corporate strategy.

Conditions

Interventions

Sponsor

Sosei